Incyte (INCY) Common Equity (2010 - 2026)
Incyte (INCY) reported Common Equity of $5.6 billion for Q1 2026, up 53.31% on a YoY basis from $3.7 billion in Q1 2025, and up 8.81% quarter-over-quarter from $5.2 billion in Q4 2025.
Incyte (INCY) Common Equity (2010 - 2026) Analysis & Trends
Incyte has reported Common Equity for 17 years, with the latest figure at $5.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 53.31% year-over-year to $5.6 billion; the trailing twelve-month figure through Mar 2026 stood at $5.6 billion (up 53.31% YoY), and the FY2025 full-year result was $5.2 billion, up 49.89% from the prior year.
- Common Equity for Q1 2026 stood at $5.6 billion, up from $5.2 billion in the prior quarter.
- The five-year high for Common Equity was $5.6 billion in Q1 2026, with the low at $3.0 billion in Q2 2024.
- Historically, Common Equity has averaged $4.4 billion across 5 years, with a median of $4.4 billion in 2022.
- Annual changes were most pronounced in 2024 — Common Equity slumped 36.78% — and 2026, when it surged 53.31%.
- Incyte's Common Equity stood at $4.4 billion in 2022, then rose by 18.76% to $5.2 billion in 2023, then sank by 33.57% to $3.4 billion in 2024, then surged by 49.89% to $5.2 billion in 2025, then climbed by 8.81% to $5.6 billion in 2026.
- The last three Common Equity figures came in at $5.6 billion (Q1 2026), $5.2 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 5.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.62 Bn |
| Dec 31, 2025 | 5.17 Bn |
| Sep 30, 2025 | 4.65 Bn |
| Jun 30, 2025 | 4.17 Bn |
| Mar 31, 2025 | 3.67 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 3.17 Bn |
| Jun 30, 2024 | 3.00 Bn |
| Mar 31, 2024 | 5.39 Bn |
| Dec 31, 2023 | 5.19 Bn |
| Sep 30, 2023 | 4.93 Bn |
| Jun 30, 2023 | 4.74 Bn |
| Mar 31, 2023 | 4.46 Bn |
| Dec 31, 2022 | 4.37 Bn |
| Sep 30, 2022 | 4.23 Bn |
| Jun 30, 2022 | 4.09 Bn |
| Mar 31, 2022 | 3.86 Bn |
| Dec 31, 2021 | 3.77 Bn |
| Sep 30, 2021 | 3.15 Bn |
| Jun 30, 2021 | 2.94 Bn |